Compare C3.ai Inc (AI) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Quest Diagnostics Inc — how do they compare? C3.ai Inc trades at $10.25 (market cap $1.65B), while Quest Diagnostics Inc trades at $237.26 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 15.9× C3.ai Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals.
| AI | DGX | |
|---|---|---|
Market Cap | $1.65B | $26.21B |
Sector | Technology | Health |
52-Week High | $19.66 | $238.50 |
52-Week Low | $7.76 | $173.49 |
Enterprise Value | $1.08B | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.25, down 1.44% on the day, with mixed technical signals showing bullish moving averages but overbought RSI readings. The company maintains strong revenue growth, reaching $389 million in 2025, but continues to report significant losses with a -74.21% net margin. Recent positive developments include being named a Leader in AI Platforms by Forrester Research.
While technical indicators suggest short-term bullish momentum, fundamental challenges persist with consistent negative profitability. The stock faces execution risk in achieving profitability despite growing enterprise AI adoption. Analyst consensus remains cautious with only 21% buy ratings and a $10.20 price target slightly below current levels.
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
